Donald W. Kufe, M.D.
Chairman, SAB
Dr. Kufe is a Professor of Medicine at Harvard Medical School.  He received his M.D. from the University of Rochester School of Medicine and postgraduate training at Harvard’s Beth Israel Hospital. Subsequently, he undertook extensive laboratory-based research in molecular virology at the Institute of Cancer Research of Columbia University. After Columbia University, he joined the faculty of Harvard’s Dana-Farber Cancer Institute where he has served as Chief of the Division of Cancer Pharmacology, Deputy Director of the Dana-Farber Cancer Center, Director of the Harvard Phase I Oncology Group and Leader of the Experimental Therapeutics Program. He develops new therapeutic approaches to cancer with a focus on the development of cancer drugs, vaccines and anti-angiogenic compounds. He has served as the senior editor of Cancer Medicine, the major textbook in oncology, and on the editorial boards of multiple international cancer research journals.

 

Darell D. Bigner, M.D. Ph.D.
Member, SAB
Dr. Bigner is the Deputy Director of the Duke Comprehensive Cancer Center, Professor of Surgery, Vice-Chairman of the Division of Basic Science and Investigative Pathology, Department of Pathology, Duke Medical Center, and the Edwin L. Jones, Jr. and Lucille Finch Jones Distinguished Cancer Research Professor of Pathology, Duke University. Dr. Bigner is an inventor of the anti-tenascin antibody therapeutic, Neuradiab. He sits on or chairs a variety of advisory panels and review committees at both the National Cancer Institute and National Institute of Health, and is considered a leading expert on molecular approaches to the treatment of brain cancer. He has published nearly 500 scientific articles, reviews, or books, and is currently the recipient of six NIH/NCI grants supporting his work on the pathology and treatment of brain cancer.

 

Michael R. Zalutsky, Ph.D
Member, SAB
Dr. Zalutsky is Professor of Radiology and Biomedical Engineering at Duke University. He is also Director of the Radiolabeling Shared Resource and Co-Program Leader of the Cancer Immunobiology Program in the Duke University Comprehensive Cancer Centre. He received his Ph.D. in Chemistry from Washington University and prior to coming to Duke, held academic appointments at the University of Chicago and Harvard Medical School. Dr. Zalutsky has authored or co-authored more than 260 journal articles and reviews and has edited two books. He serves on the editorial board of four journals and has been a member of the Medical Imaging Study Section of the NIH. His primary research interests are the development of molecularly targeted radiodiagnostics and radiotherapeutics for oncologic applications. His research has been supported by multiple grants from the NIH and the Department of Energy. He currently is a recipient of a MERIT Award from the NCI for his research in targeted radiotherapy. In 2005, he received the Berson Yalow Award from the Society of Nuclear Medicine.